Sintx Technologies, Inc. (SINT) AI Stock Analysis

Sintx Technologies, Inc., formerly known as Amedica Corporation, is an innovative materials company focused on biomedical, industrial, and antipathogenic applications. Headquartered in Salt Lake City, Utah, the company specializes in researching, developing, and commercializing silicon nitride-based medical devices. Its product portfolio includes solid and porous forms of silicon nitride, silicon nitride powder, coatings, and composite materials like polyetherketoneketone. Sintx Technologies aims to improve the performance, biocompatibility, antimicrobial properties, and durability of medical devices while expanding into industrial solutions through strategic partnerships and research initiatives.

Sintx reported revenue of $1.0M in FY2025, down 18.3% following a 52.6% drop to $1.2M in FY2024, after reaching $2.6M in FY2023. Gross margin turned negative in FY2025 to -19.7% from 34.9% in FY2024 and 70.2% in FY2023. Operating margin was -1053.1% in FY2025, resulting in a net income of -$17.1M. Over five years from FY2020 to FY2025, revenue grew at a CAGR of 11.4%. In the latest quarter ending June 30, 2026, quarterly revenue grew 199.3% year-over-year, while trailing twelve-month revenue stood at $1.3M with an operating margin of -638.5% and an eps of -$4.91.

As of June 30, 2026, Sintx Technologies held $3.6M in cash and short-term investments and $3.0M in total debt, leaving net cash at $541,000. Shareholders' equity was $4.8M against total assets of $10.4M, with a current ratio of 2.36 and a debt-to-equity ratio of 0.63. For FY2025, operating cash flow was -$8.6M and free cash flow was -$8.8M. Capital expenditures were $189,000 and share buybacks were $133,000, while the company's share count increased 1862.6% over five years.

Sintx Technologies carries a market cap of $13.2M and an enterprise value of $11.4M. The stock trades at a price-to-sales multiple of 9.9x and an enterprise value-to-revenue multiple of 10.5x, compared to a median price-to-sales of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 2.5x. Over the past year, the stock fell 57.2%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock dropped 100.0% compared to an 83.0% gain for the S&P 500.

Wall Street coverage consists of 3 Strong Buy ratings and 1 Buy rating. The mean price target is $9.25, which represents a 431.6% premium over the last close of $1.74 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.83 and revenue of $3.2M. For the following fiscal year, 3 analysts project revenue of $6.0M, reflecting 86.4% growth, and an EPS of -$1.08. Sintx beat EPS estimates 0 times over the last 4 quarters, with next earnings scheduled for November 11, 2026.

This page is an AI-written research summary of Sintx Technologies, Inc. (SINT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SINT income statement, SINT balance sheet, SINT key metrics, SINT analyst forecast, SINT chart. See the SINT stock overview for the latest quote and news.